Abstract: OBJECTIVE To explore the prognosis of etimicin combined with meropenem, piperacillin/tazobactam for multi-drug resistant Pseudomonas aeruginosa lung infection, so as to provide a certain guiding significance for clinic. METHODS A total of 192 patients with P.aeruginosa lung infection in our hospital from Feb. 2013 to Feb. 2015 were chosen. According to the random number table,they were divided into observation group and control group, 48 cases in each group. Etimicin was provided to the control group patients, etimicin combined with meropenem and piperacillin/tazobactam for observation group patients. The prognosis were compared in the two groups. RESULTS Effective rate in observation group was 91.67%, significantly higher than 41.67% in the control group, and mortality rate in observation group was 2.08%, significantly lower than the 18.75% in the control group (P<0.05). Hospitalization time in observation group was (20.14±11.37) d, significantly shorter than the control group (55.22±23.54) d (P<0.05). Rales and cough disappeared time, temperature and leukocytes recovery time in observation group were significantly shorter than those in control group (P<0.05). CONCLUSION The treatment of etimicin combined with meropenem and piperacillin/tazobactam for multi-drug resistant P.aeruginosa lung infection is significant, and the prognosis is good, which can significantly shorten the time of symptoms, so as to reduce hospitalization time.